Search | Clinical Trials Finder

Conditions: Opioid Use, Pain, Hypogonadism, Male
Interventions: Testosterone Undecanoate 250 MG/ML, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: AZD4076, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: T. John Winhusen, PhD; Other
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Migraine Headache
Interventions: LY2590443, Placebo injection, Sumatriptan, Placebo capsule; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Beverly Hills, California • Chula Vista, California • Fresno, California + 16 more

Conditions: Healthy
Interventions: Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 329 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Interventions: DEN4 Vaccine Candidate, DEN4 Vaccine Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Ulcerative Colitis
Interventions: Ontamalimab, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 38
States / cities: Little Rock, Arkansas • Lancaster, California • Rialto, California + 31 more

Conditions: Chronic Migraine or Episodic Migraine
Interventions: Placebo, AMG 301; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more

Conditions: Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions: Deoxycholic Acid, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Newport Beach, California • San Francisco, California • West Hollywood, California + 5 more

Conditions: HIV Infections
Interventions: MVA/HIV62B vaccine, AIDSVAX B/E vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more

Conditions: Pulmonary Hypertension
Interventions: Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Elliott, Maryland

Conditions: Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: COVID-19
Interventions: Baricitinib, Dexamethasone, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 61
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more

Conditions: Acute Pancreatitis, Systemic Inflammatory Response Syndrome
Interventions: CM-4620 Injectable Emulsion or CM-4620-IE, Placebo; Drug · Other
Lead sponsor: CalciMedica, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 27
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 21 more

Conditions: Asthma
Interventions: omalizumab, omalizumab placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 20 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 8
States / cities: Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Osteoarthritis
Interventions: sodium hyaluronate, placebo; Device
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: HIV Infections
Interventions: PENNVAX®-GP HIV-1 DNA vaccine, Interleukin-12 (IL-12) DNA adjuvant, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Decatur, Georgia • Rochester, New York • Nashville, Tennessee + 1 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 14
States / cities: Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more

Conditions: Type 2 Diabetes Mellitus
Interventions: OPK-88003, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Huntington Park, California • Los Angeles, California • Hialeah, Florida

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: HYQVIA, 0.25% albumin placebo solution with rHuPH20, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 19
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 14 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Acthar Gel, Placebo Gel; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Hemet, California • Upland, California • Fort Lauderdale, Florida + 12 more

Conditions: Staphylococcal Infections
Interventions: SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, Blood sample, SA4Ag vaccine high dose, Placebo; Biological · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 16
States / cities: Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 10 more

Conditions: Pharmacokinetics, Safety, Tolerability
Interventions: 5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo; Drug
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Psoriasis
Interventions: Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 32
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 29 more

Search by objective public record fields.

Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Study in Participants With Acute Migraines Headaches

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).

Impact of Liraglutide 3.0 on Body Fat Distribution

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Inner-City Anti-IgE Therapy for Asthma

Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC

Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Acthar Gel for Active Systemic Lupus Erythematosus (SLE)

Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment